HONG KONG, Jan 17, 2023 - (ACN Newswire via SEAPRWire.com) - On 16 January 2023, Fosun High Technology, the domestic operating entity of Fosun International Limited ("Fosun International", HKEX: 00656), and eight domestic banks held a syndicated loan signing ceremony at the Bund Finance Center, Shanghai. According to the agreement, Industrial and Commercial Bank of China, Agricultural Bank of China, Bank of China, China Construction Bank, and Bank of Communications as joint lead banks, and China Minsheng Bank, the Export-Import Bank of China, and Shanghai Pudong Development Bank, and as participating banks will jointly form a syndicate to provide Fosun High Technology a loan totaling RMB12 billion.It is reported that this is the largest private enterprise loan led by five major state-owned banks in cooperation with policy banks and joint-stock banks since the Central Economic Work Conference explicitly proposed in mid-December last year to encourage and support the development of the private economy and private enterprises.The market is generally in the view that the syndicated loan is not only of great significance to Fosun, but it also plays a positive role in improving public expectations and boosting confidence for development for private enterprises in Shanghai and even the entire country.According to the Company's official release, Guo Guangchang, Chairman of Fosun International said that this signing has further deepened the cooperation between Fosun and banks, broadened financing channels, and consolidated liquidity support for business development.Before the RMB12 billion syndicated loan was officially completed, on 13 January, Fosun High Technology successfully completed bookbuilding for the RMB1 billion super & short-term commercial paper "23 Fosun High Technology SCP001" with a term of 180 days and a coupon rate of 6.99% per annum. The super & short-term commercial paper is Fosun High Technology's first issuance since its return to the public market at the end of April 2022.Market analyst pointed out that the successful issuance of the super & short-term commercial paper and the smooth completion of more than RMB10 billion syndicates loan reflect financial institutions and investors' confidence in the stabilization of Fosun's capital and their endorsement of Fosun's strategy of streamlining the organization and focusing on its core businesses.Over the past six months or so, Fosun's series of divestment actions in the capital market have gained widespread attention. During the period, companies under Fosun significantly reduced their shareholdings in Nanjing Iron and Steel United, Jianlong, Zhaojin Mining, Tsingtao Brewery, Jinhui Liquor, Zhongshan Public Utilities, Sanyuan, and COFCO Engineering & Technology. According to incomplete statistics, Fosun's accumulative return of capital has reached tens of billions of yuan. In addition to this syndicated loan and the super & short-term commercial paper, Fosun's capital has been further consolidated.In recent years, Fosun proposed to position itself as a global innovation-driven consumer group. In the past six months or so, Fosun has significantly accelerated its pace of focusing on its core businesses in the family-oriented consumer sector. Based on recent positive news, it can be seen that this strategic adjustment has already achieved results, and Fosun's Health, Happiness, Wealth and other family-oriented consumer sectors have shown a strong recovery momentum.Taking Fosun Tourism Group in the Happiness segment as an example, on the New Year's Day this year, Atlantis Sanya, FOLIDAY Town Lijiang and other businesses have all performed better than the same period in 2022, and many Club Med resorts in China recorded close to 100% occupancy. In the global market, Club Med's bookings in the first half of 2023 have greatly exceeded the same period in 2019 before the COVID-19 epidemic.Regarding Fosun Pharma in the Health segment, its anti-epidemic vaccine and drug continue to attract great attention. COMIRNATY, including the monovalent COVID-19 mRNA vaccine (BNT162b2) and the bivalent vaccine which can protect against the Omicron variant, was officially registered as a drug/product (biological product) in Hong Kong SAR on 20 December 2022. Fosun Pharma has also opened up vaccinations to people including Mainland Chinese residents. As regards Azvudine, the oral medication for COVID-19, it is now included in the medical insurance scheme in 31 provinces, municipalities, and autonomous regions across the country, and is available in grassroots medical institutions in many provinces. The accessibility of Azvudine has been greatly enhanced.Based on its solid financial performance and strong potential for rebound, domestic and overseas securities firms have recently issued research reports, assigning Fosun International an "overweight" rating. On 12 January, Nomura Orient International Securities published a research report and mentioned that Fosun International currently has sufficient cash flow, the short-term liquidity problem has been resolved, the future leverage ratio is expected to be reduced, and the capital structure will continue to be optimized; at the operational level, Fosun will firmly focus on its core businesses in the family-oriented consumer sector. With the continuous optimization of China's epidemic prevention policy, the firm expects Fosun to achieve better performance.Previously, China International Capital Corporation (CICC) and China Industrial Securities have published research reports successively and expressed optimism about Fosun's strategy of streamlining the organization and focusing on its core businesses."In the medium and long term, we believe that the valuation method of Fosun International is expected to gradually shift from using the NAV of the group to using the PE of the large consumer company. As a result, Fosun is expected to usher in a rise in the central level of long-term valuation," CICC mentioned in the research report. Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
Hong Kong, PRC, Jan 5, 2023 - (ACN Newswire via SEAPRWire.com) - China South City Holdings Limited (the "Company" or the "Group", SEHK stock code: 1668.HK) is pleased to announce that China South International, a direct wholly-owned subsidiary of the Company, has entered into an investment agreement with Shenzhen Shenji No.1 Industrial Park Investment and Operation Co., Ltd. under Shenzhen SEZ Construction and Development Group Co., Ltd. ("SZCDG"), pursuant to which the latter has agreed to subscribe for 69.35% new shares of "China South City Xi'an" at a cash consideration of RMB5 billion (equivalent to approximately HK$5.58 billion). Upon completion of the transaction, the Group's shareholding in "China South City Xi'an" will be reduced from 100% to 30.65% and "China South City Xi'an" will cease to be a subsidiary of the Group and the transaction is subject to the approval of the independent shareholders of China South City. RMB2.86 billion of the subscription proceeds from this transaction will be used to repay the Group's shareholder loans, which will provide additional working capital for the Group, reduce the Group's gearing ratio and significantly improve its liquidity. The signing of this investment agreement marks another step forward in the cooperation between the Company and SZCDG, and represents SZCDG's strong support for the Group's operation and development. the consideration of the transaction approximates the carrying value of the net assets of China South City Xi'an as of 30 September 2022, which fully demonstrates SZCDG's high recognition of the Group's asset value and future development.As disclosed in the announcement of the Company, China South City Xi'an is principally engaged in development and operation of integrated logistics and trade centres, and is located at the Xi'an international trade and logistics park, which is an open economic pilot zone and a core area for modern service industry established with strong support from the Xi'an government. China South City Xi'an has a total planned land area of approximately 10.00 million sq. m. and the total planned GFA of approximately 17.50 million sq. m. As of 30 September 2022, China South City Xi'an has acquired land with a total planned GFA of approximately 4.17 million sq. m. and has completed the construction of approximately 2.41 million sq. m., including a commodity trading centre, a logistics park and other ancillary facilities. In addition, business operation in China South City Xi'an covers various industries, including hardware materials and machinery products, curtains and fabrics, textile and clothing, leather and fur, automobile and motorcycle parts, building and decoration materials, 1668 New Times Square, outlets, crossborder e-commerce, Central Asia and ASEAN product exhibition centre, etc., on its trade centre premises, of which the commercial complex, 1668 New Times Square, was included in Shaanxi Provincial Key Project in 2019 and 2020.During the year, SZCDG fully leveraged its strategic leadership role as a state-owned enterprise in various aspects to facilitate the Group's long-term and stable development. Firstly, in terms of senior management appointments, Mr. Li Wenxiong, chairman of SZCDG, was appointed as Co-Chairman and Non-Executive Director of the Group, while Mr. Wan Hongtao and Mr. Qin Wenzhong were appointed as the Group's Vice president and the Group's Chief Financial Officer respectively, and were also appointed as executive directors, thereby continuously strengthening the Group's senior management team. In addition, SZCDG continued to provide financial support to the Company during the year to improve the Company's operations and improve its liquidity. In May 2022, the subscription by SZCDG was officially completed, whereby the Company issued and allotted 3.35 billion new shares to SZCDG under the special mandate and subscription agreement and received total proceeds of HK$1,909.5 million, significantly improving the Company's overall capital and financial strength while welcoming a state-owned background. In July 2022, the Group entered into an agreement with SZCDG for the transfer of 50% equity interest in First Asia Pacific Group Company Limited at a consideration of RMB1,257 million; in the same month, SZCDG supported the extension of the terms of five offshore US dollat senior notes of the Company by way of keepwell agreement. In November 2022, subsidiaries of SZCDG have taken the lead in setting up an equity investment fund with a total size of approximately RMB11 billion and coordinated with the Group to work closely with relevant banks to promote the formation of a syndicated loan, thus providing another strong financial support for the Group's future growth, and the China South City Xi'an transaction is the first step under this plan.In terms of business, with the investment by SZCDG, the Company has entered into strategic cooperation with seven major enterprises, including a strategic cooperation agreement with Pengcheng Smart Sharing Technology (Shenzhen) Co., Ltd. and Shenzhen Planning Institute under SZCDG. In addition, as recommended by SZCDG, China South City reached a cooperation agreement with Shenzhen International Holdings to effectively revitalize its assets and further strengthen its cash flow by transferring its Qianlong Logistics' two high-standard logistics and warehousing projects in Zhengzhou and Hefei. By taking a series of proactive measures, China South City reduced its gearing ratio to 63.8% and recorded a net asset value of approximately HK$3.71 per share.About China South CityChina South City Holdings Limited ("China South City", stock code: 1668.HK) is a leading developer and operator of large-scale integrated logistics and trade centres in China, and has positioned itself to be "world-class integrated trade and logistics centre, digital centre, innovation centre and living centre".As an industry leader, China South City insists on serving the nation by promoting the transformation and upgrading of regional economy and new urbanisation, and has developed a diversified and flexible business model with core business formats covering professional wholesale markets, warehousing, logistics and distribution, integrated commercial, e-commerce, convention and exhibition, daily life facilities and integrated property management, etc. It has developed and operated projects in Shenzhen, Nanning, Nanchang, Xi'an, Harbin, Zhengzhou, Hefei and Chongqing. China South City has a core subsidiary, the Business Management Division, as well as various branded professional companies such as Huasheng Commercial, China South City Logistics Group, First Asia Pacific Property Management ( associated company), China South City Micro-credit and Huacaitong Digital Technology.In 2014, Tencent Holdings Limited invested in China South City, and the two parties used their respective resource advantages to start new exploration of China South City's business model; in 2022, SZCDG became the single largest shareholder of China South City, bringing the resource advantages of state-owned enterprises to China South City to start a new chapter of high-quality integrated development. For more information, please visit the Company's website at http://www.chinasouthcity.com/ Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
A non-profit project with the ultimate goal of becoming the largest digital gallery to showcase all amazing aspects of China, the country with the longest continuous history in the world New York, NY, January 04, 2023 – (SEAPRWire) – NFTs have taken over the internet. No one, from businesses to brands and celebrities, can deny onboarding the NFT bandwagon. Unlike any new NFT projects that are spawned into the market every other day, China Box chooses a completely different approach as it is dedicated to honor Chinese culture and aim to become the largest digital gallery to showcase all amazing aspects of the country with the longest continuous history in the world. China Box positions itself as a videoverse where users can watch spectacular Chinese stories and collect randomly dropped virtual items along the way. The rule of the game is very simple, like other watch-to-earn projects, the more time users spend enjoying the provided videos, the more chance they will have to receive free and exclusively designed NFTs. Product Manager of China Box excitedly commented on the launch: “As we enter a new digital era powered by blockchain, China Box sees our mission of utilizing this modern technology not only to introduce all the wonderful and amazing aspects of China to the world but also to truly incentivize people to deep dive into the stories about the country’s history, traditions and customs, latest developments, and promising future. This is the core value of our project, and it is also the key competitive advantage of China Box in the sea of watch-to-earn and NFT projects out there.“ China Box aims to give users the best experiences in their journey to explore the beauty of China. With a very user-friendly interface and easy-to-understand features, China Box’s current videoverse includes five key sections to deliver a comprehensive picture of the country: Cuisine (“Taste of China”), Technology Development (“Technology”), People (“1.4 billion”), Traditional Martial Arts (“Kung Fu”) and of course, Landscape (“Nature”). Each section consists of dozens of short-to-medium-length jaw-dropping videos which have been carefully selected. Transforming into a customizable panda warrior, users will have the chance to explore all these sections, and completely immerse into a magical Chinese-inspired virtual world. “We treat each user as a valuable ambassador of not only the project itself but also the beauty of China. Therefore, in the upcoming months, to maximize users’ experience and build a strong loyal community, China Box will keep delivering more informative videos at the highest quality; at the same time, more unique NFTs that you cannot find anywhere else will also be introduced.” Product Manager said. In 2023, besides enriching its videoverse, China Box also has a clear roadmap of introducing new features allowing users to mint NFTs, as well as NFT airdrops. China Box is another typical example of the integration between technology, artistic and cultural heritage, where blockchain and its application can play a vital role in promoting local cultural prosperity and economic development. Visit https://www.videostory.com/chinabox/ to take a look at this Chinese-inspired virtual world. Keep an eye on China Box’s twitter account to get all the latest updates: https://twitter.com/ChinaBox2022 Media Contact Brand: China Box Contact: Media team Website: https://www.videostory.com/chinabox/ SOURCE: China Box The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
HONG KONG, Dec 28, 2022 - (ACN Newswire via SEAPRWire.com) - The Hong Kong Trade Development Council (HKTDC) welcomes the upcoming plans to re-open borders between Mainland China and Hong Kong. Resumption of travel will rejuvenate the convention and exhibition sector, boosting economic activity and helping to accelerate Hong Kong's economic recovery.A spokesperson from the HKTDC said: "Given the importance of economic and social connectivity between the Mainland and Hong Kong, the resumption of quarantine-free travel between Mainland China and Hong Kong will certainly be welcomed by many international and Mainland business people who have been waiting for this good news. The unimpeded flow of international and Mainland travellers will also benefit the convention and exhibition sector.""In the past three years, the HKTDC has been organising physical and online fairs and conferences as well as support programmes to help companies continue doing business during the pandemic. With the lifting of international travel restrictions in Hong Kong in recent months, we have also seen a gradual return of overseas participants to our events. We believe more international and Mainland companies will come to Hong Kong to do business when quarantine-free travel resumes between the Mainland-Hong Kong borders. To help companies capture even more opportunities, we have lined up a full programme of business events from January onwards."Flagship conferences and fairs in January to kick off the new yearThe HKTDC will kick off 2023 with the Asian Financial Forum (AFF) and Hong Kong Toys & Games Fair, Hong Kong International Stationery and School Products Fair, Hong Kong Baby Products Fair, and Hong Kong International Wine & Spirits Fair (Special Exhibition) in January, with missions to overseas cities in February, and the Jewellery show and Filmart in March. The Spring trade show season will see several large-scale events including the inaugural InnoEX, Electronics Fair (Spring Edition) , Lighting Fair (Spring Edition), Houseware Fair, Gifts & Premium Fair in April and International Healthcare Week in May.About HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedInMedia enquiriesPlease contact the HKTDC's Communications and Public Affairs Department:Sunny Ng, Tel: +852 2584 4357, Email: sunny.sl.ng@hktdc.orgSam Ho, Tel: +852 2584 4569, Email: sam.sy.ho@hktdc.org Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
HONG KONG, Dec 19, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Company was awarded the "Most Valuable Pharmaceutical and Medical Company" at the "7th Hong Kong Golden Stocks Awards Ceremony" held in Hangzhou today.The Company Awarded the "Most Valuable Pharmaceutical and Medical Company"The "Most Valuable Pharmaceutical and Medical Company" award aims to recognize Hong Kong-listed pharmaceutical and medical companies that have a healthy corporate governance structure, prominent industry status, sound governance structure, good main business, and the ability to provide investors with sustainable and stable values. SinoMab was awarded the "Most Valuable Pharmaceutical and Medical Company", highlighting the attention and recognition of the industry and investors on the Company's value and innovation capabilities, which is a great encouragement and even a spur to SinoMab.SinoMab is the first Hong Kong-based listed biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics, primarily monoclonal antibody ("mAb")-based biologics, for the treatment of immunological diseases. With R&D headquarter in Hong Kong and production base in China, the Company strives to become a leading global biopharmaceutical company for the development of novel drugs to fulfil unmet medical needs through its Hong Kong-based innovative R&D, and PRC-based manufacturing capabilities. Currently, various candidate products for all-field indications of autoimmune diseases in SinoMab's layout have started clinical trials successively and are progressing steadily. In particular, SM03 (Suciraslimab), the Company's flagship product, is a potential global first-in target mAb for the treatment of rheumatoid arthritis ("RA") and other immunological diseases such as Alzheimer's disease ("AD"), systemic lupus erythematosus ("SLE"), Sjogren's syndrome ("SS") as well as non-Hodgkin's lymphoma ("NHL"). The Phase III clinical trial of SM03 for treatment of RA completed its enrollment on 31 December 2021, and is expected to complete the last subject visit (FV) in December 2022, read out clinical data in the first quarter of 2023 and submit a New Drug Application ("NDA") to the National Medical Products Administration (the "NMPA") of the People's Republic of China ("PRC") for commercialization in the second half of 2023 at the earliest.Under normal operation of the human immune system, the B-cell receptor (BCR) pathway would be activated and create strong signals in response to foreign ("non-self") antigens and trigger a series of B-cell immune responses. To differentiate from our "self" antigens, our body would recruit molecules, like SHP-1, to inhibit or reduce BCR-induced signaling, thereby suppressing B-cell immune responses. SM03 can be used to recruit such immunosuppressive molecules as SHP-1 by conversion of cis-binding CD22 to trans-binding CD22, forming a stable CD22 trans-binding structure, thereby restoring the tolerance of B cells to our "self" antigens and inhibiting a series of immune responses of B cells to attack our "self" antigens, thus suppressing relevant immune responses.Most of the mechanisms of action of existing RA therapies will result in the depletion or death of B cells, which can have a series of side effects on the human autoimmune system. In contrast, SM03 suppresses the autoimmune response by regulating the function of B cells and does not damage the B-cells and does not affect the normal function of B-cells in the immune system. Data from the Phase II clinical trial showed that SM03 has a comparable response rate and a significant safety advantage over competing products currently available on the market.In addition, SN1011, a key product of the Company, has obtained four IND approvals from the NMPA for the treatment of SLE, pemphigus ("PV"), multiple sclerosis ("MS"), neuromyelitis optica spectrum disorder ("NMOSD") respectively. At the same time, the Company is planning an IND submission for MS in the U.S. SM17 (a humanized anti-IL-7RB monoclonal antibody for injection), another key product of the Company, its first healthy subject had been successfully dosed in a Phase I First-in-Human (FIH) clinical trial in the U.S. in June this year and the subjects are currently in normal condition.Previously, SinoMab appointed Mr. Shanchun WANG as the President (China) of the Company, mainly responsible for the China operation. Mr. Wang has rich experience in the pharmaceutical industry for more than 30 years, served as the executive director of Sino Biopharmaceutical Limited and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., and is a specialist that granted the special government allowances of the State Council and awarded as a national model worker. SinoMab's dedication to the field of autoimmune diseases and its vision of growing into a global leader in novel treatments of immunological diseases is highly consistent with the development model of Mr. Wang's service enterprises in the past. As one of the leaders in the biopharmaceuticals enterprise in China with rich experience and practical achievements in corporate strategic management, organizational management, innovation research and development and product commercialization, Mr. Wang's engagement as the President (China) of the Company will help expediting the Company's development from a global drug research and development enterprise to a biopharmaceutical company bearing commercialization capabilities and international perspective.Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: "The Company is deeply honored to be awarded the "Most Valuable Pharmaceutical and Medical Company" in the selection of the "7th Hong Kong Golden Stocks Awards", which reflects the capital market's recognition of the Company's value, innovation capabilities and growth potential, and is a great encouragement to the Company. In the future, the Company will, in line with its original purposes, endeavor to discover and develop innovative drug targets, explore therapies for immune diseases, accelerate R&D and clinical trials of various products, and at the same time further expand the product pipeline and potential indications, accelerate the realization of product commercialization, strive to bring benefits to patients and create values for shareholders and investors. With the imminent completion of the Phase III clinical trial of its flagship product SM03, the Company is poised for a new leap of increase in value."About the Selection of the "7th Hong Kong Golden Stocks Awards"The selection of the "7th Hong Kong Golden Stocks Awards" was jointly organized by Zhitongcaijing.com, a leading Hong Kong and US stock information platform in China, with RoyalFlush Finance and China Galaxy Securities. This selection was rigorous and attracted over 1,000 entries from Hong Kong-listed companies, covering traditional industries such as petrochemicals, finance, and automobiles, as well as emerging industries such as chips, Internet, and medical and pharmaceuticals, which are leading the transformation of China's economy.About SinoMab BioScience LimitedSinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Alzheimer's disease, systemic lupus erythematosus (SLE), pemphigus (PV), multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
HONG KONG, Dec 12, 2022 - (ACN Newswire via SEAPRWire.com) - InvesTech Holdings Limited ("InvesTech Holdings"; together with its subsidiaries, "the Group"; Stock Code: 1087.HK), a leading integrated smart-IT solutions provider in China, is pleased to announce that its subsidiary Wafer Systems Limited ("Wafer Systems"), which owns the smart office software solutions flagship product Virsical, has signed a strategic cooperation agreement with NTT Communications China ("NTT Com China"), a subsidiary of Japan's Nippon Telegraph & Telephone ("NTT"), to carry out in-depth cooperation in the field of smart-office software as a service ("SaaS"). The cooperation agreement will encompass activities including product distribution, market promotion, technical resourcing and other mutually beneficial undertakings.The Smart Office Management SaaS Service Platform is a smart operations and management platform self-developed by Wafer Systems, grounded in enterprises' common office scenarios and which uses lightweight SaaS applications to meet enterprises' operational and maintenance requirements in daily administrative management, including such functions as conference management, work station management and visitor management. Spatial visualisation maps and data report in all dimensions provided by the platform can help enterprises review their operating conditions visually, effectively support their decision-making upgrades, and assist them in reducing costs and boosting efficiency. Meanwhile, Wafer Systems' powerful product matrix and research & development ("R&D") capabilities can provide expansion capacity for products and scenarios benefiting from the deployment of the SaaS platform.As a leading provider of smart office solutions in China, Wafer Systems has been deepening its achievements in the field of smart offices to meet enterprises' needs in intelligent operations, employee health, collaborative efficiency, carbon emissions reduction, energy conservation and the user experience. The provision of integrated product matrix, its strong R&D capabilities, large customer base and extensive ecological cooperation network contribute to its core competitiveness.NTT Com China is a wholly-owned business subsidiary of NTT, the largest telecommunications service provider in Japan. Focused on providing professional ICT solutions and services for multinational enterprises running businesses in China, NTT Com China has built a complete business line of communication systems, a leading-edge operations service system, substantial overseas resources, business integration capabilities, and comprehensive marketing channels within China and elsewhere. The co-launch of the Smart Office Management SaaS Service Platform by both parties is expected to give full play to their respective advantages and jointly build out the platform so that it caters for the full range of scenarios and products that make smart offices optimally operational in order to escort enterprises' digital transformation.Amid the continuous development of the digital economy and constant changes in the economic environment, digital transformation has become the only development path for traditional industries, and the use of digital enabling technology by enterprises to reduce costs and increase efficiency has become ubiquitous. Against this backdrop, Wafer Systems and NTT Com China have jointly reached a cooperation agreement to smooth the digital transformation journey for traditional enterprises and address their need to engage with cloud computing. Looking ahead, the two parties will continue to deepen their cooperation. As it comprehensively improves the customer experience and service innovation, the two parties strive to solve problems for enterprises in the cloud, and achieve joint contribution, collaboration and win-win outcomes.About InvesTech Holdings LimitedInvesTech Holdings Limited (Stock Code: 1087.HK) was listed on the main board of Hong Kong Stock Exchange in 2010. As a leading integrated smart IT solutions provider with more than 30 years of experience in IT industry, the Group is principally engaged in IT infrastructure system integration and smart office software solutions businesses. The Group has strong presence in China, with more than 10 offices nationwide with a research and development centre in Xi'an. Website: http://www.investech-holdings.com/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
INspire HK: Future Ready Talent initiative will develop talent to build Hong Kong's 'eight centers' HONG KONG, CHINA, Dec 7, 2022 - (ACN Newswire) - This year marks the 25th anniversary of Hong Kong's return to the motherland and Deloitte's 50th anniversary in Hong Kong. To celebrate this landmark, Deloitte today announces the launch of a new talent development initiative - INspire HK: Future Ready Talent - with a commitment to empower 10,000 Hong Kong secondary school students in the next five years to become future-ready talent with strong national connectivity and a global vision. Through a diversified, one-of-a-kind learning experience, INspire HK: Future Ready Talent focuses on boosting local young talent's 'future skills' by enhancing their knowledge of advanced technology and innovation capabilities, equipping them with a global mindset to promote national development. With the arrival of the digital economy, many countries have in recent years introduced strategies to compete for talent to build an innovative economy. Amid a shortage of talent, the HKSAR Government rolled out a series of aggressive measures in the recent Policy Address to attract high-caliber global talent to Hong Kong, with a view to furthering the development of the 'eight centers' and integration into the national economy, while injecting new impetus into local economic growth and diversification. Deloitte China CEO Patrick Tsang says, "As a locally-rooted and globally connected integrated professional services organization, Deloitte China has been steadfast in fulfilling our corporate social responsibility to support China's strategy on developing a quality workforce in the new era for robust and sustainable growth." "Hong Kong is where we laid the foundation for our success today, and we continue to be committed to contributing our strengths to develop the next generation of local talent, and support Hong Kong's future growth and prosperity. In addition to our participation in the HKSAR Government's Strive and Rise Programme(1), with our strong local and global networks, deep market insights, and advanced digital capabilities, INspire HK: Future Ready Talent can become an impactful platform to nurture future-ready young talent for Hong Kong." An integral part of Deloitte's INspire HK strategy(2), INspire HK: Future Ready Talent supports the development of secondary four to six students through a series of diversified training and learning activities, aiming to help them enhance their international perspectives, understand emerging technologies and business trends, and broaden exposure to work environments across geographies. Combining theory and practice, the program will offer interactive online and offline learning courses, job shadowing, visits to Deloitte offices in China, as well as Deloitte University in Beijing and its sister institutions around the world. Besides providing traditional business and financial knowledge, the program will be structured around Hong Kong's 'eight centers' positioning, covering the 'ABCDEF' concepts (AI, blockchain, cloud, data analytics, ESG, fintech, etc) to help students become 'future-ready' talent by strengthening key 'future skills' in sustainable development, innovative technology, and digital. The program will also help students gain insights into the development and prospects of various markets, while encouraging them to expand their horizons and cultivate creative, multi-perspective thinking to create more future opportunities. Tsang says, "Established on the concept of 'National Connection. Global Vision. INspiring youth to shape a better future', INspire HK: Future Ready Talent not only demonstrates our commitment to talent development, but also reflects our confidence in Hong Kong and aspiration to create a brighter future for a city that we are proud to call our home for 50 years." Note: (1). 'Strive and Rise': Deloitte Foundation Hong Kong uplifts youth for brighter futures | Deloitte China | Newsroom (Deloitte.com) (2). Deloitte announces HKD1 billion strategic investment in Hong Kong | Deloitte China | Newsroom (Deloitte.com) About Deloitte China Deloitte China provides integrated professional services, with our long-term commitment to be a leading contributor to China's reform, opening-up and economic development. We are a globally connected and deeply locally-rooted firm, owned by its partners in China. With over 20,000 professionals across 30 Chinese cities, we provide our clients with a one-stop shop offering world-leading audit & assurance, consulting, financial advisory, risk advisory, business advisory and tax services. We serve with integrity, uphold quality and strive to innovate. With our professional excellence, insight across industries, and intelligent technology solutions, we help clients and partners from many sectors seize opportunities, tackle challenges and attain world-class, high-quality development goals. The Deloitte brand originated in 1845, and its name in Chinese denotes integrity, diligence and excellence. Deloitte's professional network of member firms now spans more than 150 countries and territories. Through our mission to make an impact that matters, we help reinforce public trust in capital markets, enable clients to transform and thrive, and lead the way toward a stronger economy, a more equitable society and a sustainable world. About Deloitte Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited ("DTTL"), its global network of member firms, and their related entities (collectively, the "Deloitte organization"). DTTL (also referred to as "Deloitte Global") and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Deloitte Asia Pacific Limited is a company limited by guarantee and a member firm of DTTL. Members of Deloitte Asia Pacific Limited and their related entities, each of which are separate and independent legal entities, provide services from more than 100 cities across the region. Please see www.deloitte.com/about to learn more. Disclaimer This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited ("DTTL"), its global network of member firms or their related entities (collectively, the "Deloitte organization") is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No representations, warranties or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of DTTL, its member firms, related entities, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. DTTL and each of its member firms, and their related entities, are legally separate and independent entities. 2022. For more information, please contact Deloitte China. Contact: Ashley Leung Tel: +852 2109 5261 Email: asleung@deloitte.com.hk Contact: Lyanna Chan Tel: +852 2238 7111 Email: lyachan@deloitte.com.hk
ROCKVILLE, MD and SHENZHEN, CHINA, Nov 16, 2022 - (亚太商讯 via SEAPRWire.com) - 君圣泰（HighTide Therapeutics Inc.）宣布，公司核心品种HTD1801在成人原发性硬化性胆管炎（PSC）患者中完成的临床II 期研究结果在知名国际期刊《美国胃肠病学杂志》发表。该研究达到首要研究终点和多个关键的次要研究终点，从而揭示HTD1801治疗 PSC的有效性和安全性。临床终点指标中，血清碱性磷酸酶（ALP）是一种与PSC 疾病严重程度密切相关的关键生物标志物。研究数据显示，相较安慰剂组，HTD1801治疗组患者的ALP水平都显著降低。此外，HTD1801治疗明显降低丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）和 γ-谷氨酰转移酶（GGT）。这进一步支持HTD1801对PSC的治疗潜力。在本研究中，PSC患者未出现由研究药物导致的严重不良反应，对HTD1801表现出良好的安全性和耐受性。美国西北肝脏研究所所长（Liver Institute Northwest）兼牵头研究者、医学博士 Kris Kowdley教授表示：“PSC 的治疗存在巨大的未满足需求。本次研究中，HTD1801 对ALP改善和优异的安全性彰显该化合物可预期的成药前景。此外，本项试验结果为未来开展HTD1801治疗PSC的进一步确证性研究奠定了坚实的基础。”君圣泰创始人兼首席执行官刘利平博士表示：“我们的研究结果发表在《美国胃肠病学杂志》令人鼓舞。很高兴与大家分享这个消息。PSC目前尚无获批药物。广大患者迫切需要有效的治疗方法。该研究积极的数据结果为我们继续推动HTD1801治疗PSC的相关研究工作提供了有力支持。相信在治疗期更长的临床研究中，HTD1801将为PSC患者带来进一步临床获益。” 关于原发性硬化性胆管炎原发性硬化性胆管炎（PSC）是一种慢性、进行性肝病。其特征为肝脏内胆管和/或外胆管出现进行性炎症和纤维化，进而导致多灶性胆管狭窄。多数患者最终会发展为肝功能衰竭、肝硬化，同时患恶性肿瘤的风险明显增加。PSC患者多伴发包括溃疡性结肠炎和克罗恩病在内的炎性肠病（IBD）。大量研究证明肠道菌群失衡在疾病的发病和进展中至关重要。目前，PSC尚未获批有效治疗药物，存在巨大的未满足需求。肝移植是目前对于PSC晚期患者唯一有效的治疗方案。关于君圣泰君圣泰是一家全球一体化的临床阶段生物技术公司，专注代谢性疾病、消化系统疾病等领域的重大未满足临床需求。在经验丰富的国际化高管团队和世界一流的科学顾问委员会的领导下，公司立足源头创新，以患者的综合临床获益和整体健康改善为目标，开发“First-in-Class”多靶点原创新药。基于自主知识产权，公司已构建丰富的产品管线，其中，核心品种创新药HTD1801正在全球推进多项中、后期临床试验，开发2型糖尿病（T2DM）、非酒精性脂肪性肝炎（NASH）、严重高甘油三酯血症（SHTG）、原发性硬化性胆管炎（PSC）等适应症。作为同类首创的多靶点新分子实体，HTD1801被美国FDA授予2项“快速通道资格认定”、1项“孤儿药资格认定”，并获得国家“十三五”“重大新药创制”科技重大专项支持。欲知更多资讯或沟通潜在合作，敬请访问 https://hightidetx.com 或垂询 pr@hightidetx.com。《美国胃肠病学杂志》https://shorturl.at/givL3 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
KUALA LUMPUR, Nov 15, 2022 - (ACN Newswire via SEAPRWire.com) - PLS Plantations Berhad trading and export subsidiary, Dulai Fruits Enterprise Sdn Bhd cemented their export and exclusive distribution agreement with COFCO Food Import Co. Ltd, the import and distribution subsidiary of China Oil and Foodstuffs Corporation (COFCO) in Shanghai.Back (L-R): Ms Zhengfeng, Mr. Eric Chan, CEO of Dulai Fruits, Ms. Wu Yiran, Vice General Manager of COFCO Food Import Co,. Ltd, Mr. Qiao Qingsong, Assistant General Manager of COFCO Food Import Co., Ltd; Front (L-R): Mr. Kenny Loh, Sales Director of Dulai Fruits, Mr. Jiao Guangyun, General Manager of Fruit Division of COFCO Food Import Co., LtdCOFCO is China's leader in the agricultural and food industry and a world leading agri-product trader with a global footprint with fully integrated value-chain. It is also China's largest food processor, manufacturer, and trader.The agreement was formalised in Shanghai, China.This exclusive distribution agreement was inked after months of extensive engagements and evaluation by COFCO. This further re-enforced PLS's track record and commitment to developing sustainable models in support of the Malaysia's food security programme, that aims to scale the production of agriculture and aquaculture produce through strategic partnerships and joint-ventures with established and experienced farms and farmers.PLS is a public-private-partnership (PPP) company which has a long history in co-operating with the State and Federal Government, and its related agencies. The major shareholder of PLS has worked with the Federal Land Development Authority (FELDA) since 1974 and also other land development and plantation agencies responsible for working with rural communities in the form of small holder farms. Part of PLS's food security programme is to foster the planting of different cash crops such as oil palm, rubber, paddy, cocoa to forest plantations, and promote related economic activities such food processing.Present for the signing of the agreement today at Shanghai are Ms. Wu Yiran, the Vice General Manager of COFCO Food Import CO., Ltd, whilst Mr Eric Chan, CEO of Dulai Fruits are on site as representatives of the Group. Ms. Wu Yiran of COFCO said, "The demand for durian in China has been growing over the years, where in the span of four (4) years between 2017 and 2020, China's annual import value of fresh durian has increased more than threefold. In fact, the General Administration of Customs saw the People Republic of China (PRC) importing 822 million kilogrammes of durian in 2021, which translates to an import value of $4.2 billion. With the local demand for fresh durian likely to continue increasing, we pleased to finalise this exclusive distributorship agreement which this partnership will ensure a steady supply of fresh, high-quality fruit and products, specifically for unique varieties of durian that can only be grown in Malaysia such as Musang King, Red Prawn, and D24, to name a few.PLS is the only listed company in Malaysia that is sponsoring the food security programme and owns durian plantations. Dulai Fruit, a GTC certified company by PRC and is one of the pioneers certified to export durian from Malaysia to China. In addition, Dulai Fruits also has a noteworthy track record as a major processor and exporter of durian to China, especially their experience and expertise in developing frozen durian products and deep industry experience in cold chain logistics and warehousing.With this exclusive distribution partnership, both PLS and COFCO aim to achieve an annual growth rate of 30% (annual import volume of 200 million yuan) in all types of durian imported from Malaysia over the next three (3) years. This will lay a good foundation for bilateral investment in agriculture between the two parties moving forward, and together the two countries - China and Malaysia - will make proactive contributions to the development of the Belt and Road Initiative. Lee Hun Kheng, Group CEO of PLS said, "We have been working with COFCO prior to the pandemic and are pleased to be certified under China's rigorous quality and food safety requirements. China's emphasis on food security sets a high bar in terms of quality from its suppliers globally. This agreement is a significant milestone for PLS as it further established our long-term strategy to develop a comprehensive, end-to-end agrofood ecosystem that will support the production, processing and distribution of our products locally and internationally." Lee added, "Through COFCO, Malaysia's durian will be distributed to China's most populous cities and provinces, reaching a potential audience in Beijing, Shanghai, Guangzhou and Shenzhen. This milestone is another step towards our goal to be a leading agrofood producer in which, our fresh, high quality durian fruit and products forms the backbone.""This will also be an opportunity for PLS to distribute Malaysian produce to China and the world, whilst ensuring that Malaysians continue to have access to affordable, quality produce. We are looking forward to putting Malaysia on the global map in terms of our local produce, especially our unique durian varieties, and to grow Malaysia's durian market share in one of the world's largest countries and markets. We are working hard to ensure that we meet the booming food and durian demand in both China and Malaysia, and are also optimistic that this partnership will be one of the many we will establish as we continue our expansion into different cash crops", Lee said.Eric Chan, CEO of Dulai Fruits said, "We are very excited to be here and to co-operate with COFCO and COFCO Food to increase the access to, and availability of Malaysia's unique durian offerings across the different provinces in China to cater to rising demand. Prominent varieties such as Musang King, Tekka, and Black Thorn, among others, are unique to Malaysia due to our country's climate, rainfall patterns and water source to its distinct soil composition around our Titiwangsa mountain range." Eric added, "This environment and geographical combination enable different durian varieties to thrive and produce the exceptional unique tastes and flavours that our high-quality Malaysian durians are increasingly known for. We are confident that this partnership will open more opportunities for Dulai Fruits to offer new and innovative products that will fortify Malaysia's position as the producer of top-quality durians globally."COFCO, founded in 1949, is the leader of the agricultural and food industry in China, and one of the world's leading agri-product traders. COFCO's unique advantages in global distribution, fully-integrated value chain, and agricultural innovations, as well as its seat in the world's largest emerging market make it one of the world's leading agribusinesses, ready to build even more stable food corridors between major production areas and emerging markets.PLS Plantations Berhad: 9695 / [BURSA: PLS], https://plsplantations.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
HONG KONG, Nov 14, 2022 - (ACN Newswire via SEAPRWire.com) - China Resources Pharmaceutical Group Limited ("CR Pharmaceutical" or the "Group") (stock code: 3320) has announced that the Group will once again be included as a constituent stock of the MSCI China Index, which will become effective after the market close on 30 November 2022.The MSCI Indexes are key benchmarks for institutional investors investing in the global equity markets, and cover companies with positive operating performance and solid potential. The selected stocks must meet the market capitalization, liquidity and free-float requirements, and thus have a high reference value. The MSCI China Indexes consist of a range of country, composite and non-domestic indexes for the Chinese market, intended for both international and domestic investors, including Qualified Domestic Institutional Investors (QDII) and Qualified Foreign Institutional Investors (QFII) licensees. The indexes are calculated according to the MSCI Global Investable Market Indexes (GIMI) Methodology.The inclusion of the Group in the MSCI China Index reaffirms the market's recognition of the Group's business development. CR Pharmaceutical's share price has been on a valuation recovery trajectory since 2022. The Group's innovative and transformative strategy and stable business performance have been widely recognized by the market. As at the end of October, the Group's market capitalization increased by almost 50% compared with the beginning of the year, and stock activity also increased year-over-year. As a result of this inclusion in the MSCI China Index, a large number of passive indices funds are expected to purchase the Company's shares. This will further improve the Company's performance in the stock market.In the future, CR Pharmaceutical will uphold its mission of "being the guardian of human health and improving quality of life". It will continue to optimize its business structure and consolidate its leading position in the industry with R&D innovation and investment in M&A as its engines. This will bring favorable returns to its shareholders and contribute to the growth of the health industry in China.China Resources Pharmaceutical Group LimitedChina Resources Pharmaceutical Group Limited ("CR Pharm", stock code: 3320) is a leading integrated pharmaceutical company in China. It primarily engages in the research and development, manufacturing, distribution and retailing of an extensive range of pharmaceutical and healthcare products. CR Pharm is one of the largest pharmaceutical enterprises (manufacturing 600 products), the largest manufacturer of over-the-counter drugs and the third largest distributor of pharmaceutical products in China. Its pharmaceutical distribution network comprises approximately 200 subsidiaries, and covers 28 provinces, municipalities and autonomous regions in the country, distributing products direct to local hospitals and other medical institutions. It also operates one of the largest retail pharmacy networks in China, consisting of 787 pharmacies under premium brands including "Dexin Pharmacy" and "CR Care", and 221 of them are DTP pharmacies. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
TJI Announces FY2023 Interim Results, Revenue Up 6.8% to HK$1,261.7 million despite Market Headwinds
HONG KONG, Nov 11, 2022 - (ACN Newswire via SEAPRWire.com) - Tam Jai International Co. Limited ("TJI" or the "Company", and together with its subsidiaries, the "Group"; HKEX stock code: 2217), a leading and renowned mixian-specialised fast-casual restaurant chain, today announced its interim results for the six months ended 30 September 2022 ("1H2023" or the "Period"). Revenue of the Group recorded a stable growth of 6.8% to HK$1,261.7 million despite the strong headwinds brought about by COVID-19-related restrictions and a weaker global economy. HighlightsAssuring results in 1H2023-- Revenue of the Group recorded a stable growth of 6.8% to HK$1,261.7 million despite the strong headwinds brought about by COVID-19-related restrictions and a weaker global economy. -- Operating profit of restaurant operations recorded HK$215.5 million, with the operating profit margin at 17.1%.-- Profit for the Period was HK$82.8 million. Hong Kong business maintained a steady profit margin, while revenue of Mainland China and overseas markets were increasing. Operating profit margin is expected to stabilise in 2H2023 with the gradual recovery quarter from quarter by maintaining high operational efficiency.Development remained on-track-- As at 30 September 2022, there were 208 self-owned restaurants in operation across Hong Kong, Mainland China, Singapore, and Japan, a net increase of 51 restaurants as compared to 30 September 2021.-- The restaurant network expansion has been on track, and the Group is well-equipped with the infrastructure and talents to execute the development plan in accordance with the listing mandate.-- In 2H2023, the growth momentum is expected to continue. The Group keeps long-term growth in mind while remaining prudent to keep its business profitable and winning through stability.The increase in revenue was mainly driven by the Group's restaurant network expansion, with Hong Kong being the main revenue contributor. Profit for the Period was HK$82.8 million (1H2022: HK$137.9 million). Basic earnings per share were HK6.2 cents in 1H2023 (1H2022: HK13.8 cents).Steady Hong Kong Business in Challenging TimesThe 5th wave of the COVID-19 pandemic had a lingering effect in Hong Kong during the Period. Together with the adverse market sentiment due to the global and local economic downturn, the overall consumption sentiment had deteriorated, which had hindered the recovery pace of the overall retail consumption and food and beverage (F&B) industry in Hong Kong. This softened the Group's same-store revenue. However, with the gradual recovery quarter from quarter, the Group maintained a steady pace of growth in opening new restaurants, and its revenue target has been met. Hong Kong business continued to deliver a stable profit despite the pressure of global inflation.Bumpy Overseas and Mainland China Markets DevelopmentDespite the solid growth of the Group's Singapore business, negative growth was recorded in the Mainland China and overseas markets. The business in Mainland China, in respect of which high growth potential was expected, was heavily restrained by COVID-19 related policies, such as cities or district lockdowns and the policies of daily mandatory PCR tests that had affected the Group's performance. In Japan, the Group incurred extra market entry expenses due to the delay of the opening of 2 restaurants, and the business was hit by the surge of COVID-19 cases during the second quarter. The Group has adjusted down its pace of development in Mainland China and Japan while maintaining the momentum of growth for long term. The Group has high hopes on potential in Mainland China and overseas markets, with the infrastructure and foundation established, including branding and marketing, talent recruitment, and staff training, the Group is well equipped for the growth in future. Cautious and Strategic DevelopmentThe Group has been expanding its restaurant network with caution and clearly defined strategic goals, aiming to achieve long-term growth while keeping its business profitable.During 1H2023, the Group opened 19 new restaurants in Hong Kong, 9 in Mainland China, 5 in Singapore, and 2 in Japan, respectively, bringing the total number of restaurants to 208 as at 30 September 2022, meeting the restaurant network expansion targets in Hong Kong. Maintaining High Cost-efficiency and ProductivityThe Group was able to largely mitigate the impact of the recent wave of inflation with flexibility and innovation by implementing various measures, including direct sourcing and ingredients adaptations, partnering with selected original equipment manufacturer ("OEM") suppliers, and sourcing ingredients substitution of same or better quality and at a lower cost. These measures helped minimise logistics hiccups and costs and mitigated the risk of supply chain disruption.Meanwhile, the Group managed to maintain a stable staff cost percentage while maintaining restaurant number growth and a higher number of sick days with employees contracted COVID-19. The pressure was lightened through the Group's smart rostering system, which improves cost efficiency in staff management.ProspectsEver since the start of the pandemic, TJI has been dedicating itself to the optimisation of its business processes, cost controls, and supply chain management while pushing forward its commitment to restaurant network expansion. Despite all the challenges arising from the pandemic and global economic downturn, the Group is well-positioned for steady growth and recovery through agile management, prudent restaurant network expansion, and impactful brand-building.In Hong Kong, the Group's profit margin is expected to stabilise with the implementation of various cost-control measures and the improvement of restaurant-level operation. Sales has picked up quarter-on-quarter during the Period, and the growth momentum is expected to continue well into 2H2023, along with the gradual easing of social distancing policies.The Group's encouraging performance in Singapore during the Period has demonstrated the viability of its operation model in the overseas markets. With the infrastructure and foundation that the Group has established, including branding and marketing, talent recruitment, and staff training, it is highly optimistic about the potential in Mainland China and overseas markets and anticipates resilient growth in the future when the markets recover.Mr. Daren Lau, Chairman and Chief Executive Officer of TJI, said, "We have persisted through the severe test on the resilience of our business, and yet grasped the opportunities that can maximise our potential for success. Looking forward, we believe that all the adversities shall pass, and the solid foundations we have laid shall elevate us to new height."About Tam Jai International Co. Limited (HKEX: 2217)TJI has been listed on The Stock Exchange of Hong Kong Limited (stock code: 02217.HK) since October 2021. It is one of the largest and most popular fast casual resturant chains and the No.1 Asian noodle specialty restaurant operator in Hong Kong.* It primarily operates the TamJai Yunnan Mixian and TamJai SamGor Mixian brands, with operations in Hong Kong, Mainland China, Singapore and Japan. As at 30 September 2022, the Group operated a total of 208 restaurants. With the first TamJai Yunnan Mixian restaurant and the first TamJai SamGor Mixian restaurant opened in 1996 and 2008 in Hong Kong respectively, it has pioneered and popularised the new mixian trend in Hong Kong. *In terms of both revenue and number of restaurants in 2020, according to Euromonitor Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
SHANGHAI, Nov 7, 2022 - (JCN Newswire via SEAPRWire.com) - Honda today exhibited the world premiere of the e:N2 Concept, the concept model for the second set of its e:N Series models, the Honda-brand EV model series in China, at the Fifth China International Import Expo, which began today in Shanghai, China. The exterior design of the e:N2 Concept features sharp and dynamic body lines and surface finishing which highlights the metallic look, aiming to present new styling that does not belong to any existing categories. The interior was designed with an aim to realize the value of this EV as a "space" where occupants can enjoy "intellectual exhilaration." To this end, a clean and uncluttered digital cockpit was adopted, and smart hospitality for the occupants will be offered with the latest Honda CONNECT features as well as the effective presentation of lighting and scents.As for driving performance, built on the e:N Architecture F, a dedicated architecture developed exclusively for the e:N Series, the e:N2 Concept was designed to achieve unique driving pleasure, enabling the driver to enjoy a strong "sense of unity with the vehicle." This was realized based on the dynamics technologies of Honda, including outstanding vehicle stability and crisp handling.Comments by Toshihiro Mibe, Director, President and Representative Executive Officer of Honda Motor Co., Ltd.: "The e:N2 Concept represents the value of our e:N Series, which will 'redefine the fun EVs can offer to customers' with their unique driving pleasure, the value as a mobility space and design. In China, Honda will continue delivering a broad range of electrified mobility products unique only to Honda and experience our rebirth into an electric mobility brand." Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
HONG KONG, Nov 4, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, Mr. Shanchun WANG has been appointed as the President (China) of the Company. Mr. Wang will mainly be responsible for the China operation.Mr. Shanchun WANG, served as the executive director of Sino Biopharmaceutical Limited (stock code: 1177) and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., joined SinoMab lately as the President (China) of the Company. Mr. Shanchun WANG has rich experience and practical achievements in corporate strategic management, organizational management, innovation research and development and product commercialization. He is a specialist that granted the special government allowances of the State Council and awarded as a national model worker, a Jiangsu Province Technology Advanced Worker, a Jiangsu Province Model Labour, a winner of the Shanghai Technology Advancement First Honour Award, a Jiangsu Province Outstanding Entrepreneur, a Jiangsu Province Young and Middle-aged Expert with Outstanding Contribution, a Jiangsu Advanced Individual with Outstanding Contribution in Manufacture etc. Mr. Shanchun WANG said that: "Under the leadership of Dr. Shui On LEUNG, SinoMab has gathered a very strong R&D force, forged a unique B-cell therapeutic platform, and prospectively launched a pipeline with a series of potential key products, with truly internationally recognized original innovation strength. At the same time, SinoMab's dedication to the field of autoimmune diseases and its vision of growing into a global leader in novel treatments of immunological diseases is highly consistent with the development model of my service enterprises in the past, which is also an important reason why I chose to join SinoMab." Dr. Shui On LEUNG said that: "It is a great pleasure to have Mr. Shanchun WANG joining the Company. Our Group has been engaging extensively in the field of autoimmune disease and with the mission of growing into a global leader in the novel treatments of immunological diseases. We have a strong research and development capabilities. Leveraging on our Group's B-cell therapeutic platform, Alarmins-pathway therapeutic platform and selective T-cell therapeutic platform, the Group has a strategic plan in expanding and diversifying our product pipeline. We believe that Mr. Wang's rich experience in the pharmaceutical industry for more than 30 years, and as one of the leaders in the biotech industry in China, will help expediting the Company's development from a global drug research and development enterprise to a biopharmaceutical company bearing commercialization capabilities and international perspective. Mr. Wang's engagement as the President (China) of the Company while also subscribing shares of the Company also reflects the confidence and commitment of Mr. Wang and our senior management towards the long-term and sustainable growth of the Group, and the continuous support of our senior management will be beneficial to the long-term business development of the Group."The Company entered into a subscription agreement with Mr. Wang earlier. Pursuant to the subscription agreement, Mr. Shanchun WANG conditionally agreed to subscribe for and the Company conditionally agreed to allot and issue 14,340,000 subscription shares. This reflects his confidence and commitment towards the long-term and sustainable growth of the Group. About SinoMab BioScience LimitedSinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus, non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
HONG KONG, Oct 31, 2022 - (ACN Newswire via SEAPRWire.com) - Kidsland International Holdings Limited ("Kidsland" or the "Company", together with its subsidiaries, the "Group", stock code: 2122), the largest toy retailer and distributor in Mainland China, is pleased to announce the appointment of Ms. Zhong Mei ("Ms. Zhong"), currently an Executive Director of the Company and the Managing Director of Kidsland in Mainland China, as Co-Chief Executive Officer of the Company, effective 1 November 2022. Ms. Zhong MeiMs. Zhong joined the Group in July 2001 and has held a number of leadership roles in various business areas over the past 20 years. She was appointed as an Executive Director in 2017 and currently heads up the Group's Mainland China operations as Managing Director. The Board believes that Ms. Zhong's extensive experience in and in-depth knowledge of global toy market will help Kidsland continue to strengthen its competitiveness and support the ongoing growth and development of the Group's business. Mr. Lee Ching Yiu, Chairman and CEO of Kidsland, said, "We are delighted to announce the appointment of Ms. Zhong as the new Co-CEO of Kidsland. Her broad experience in global toy market makes her well placed to drive our business strategy forward and strengthen the relationships with our business partners around the world. Though the economy and market sentiment remain uncertain, we believe that, with our solid foundation and reputation in the industry, as well as the leadership of our experienced management team, Kidsland will be able to bring fruitful returns to its stakeholders in the long run." About Kidsland International Holdings Limited (stock code: 2122)Kidsland International Holdings Limited ("Kidsland" or "the Group") is engaged in the retail, wholesale, e-commerce and brand operation of toys and related lifestyle products in China. As a leading toy retailer and distributor in China, Kidsland has over 20 years of industry experience and represents a portfolio of world-renowned, category-leading brands. The Group owns a well-established online and offline sales network in China. Currently, its self-operated offline retail system includes kidsland stores, LEGO Certified Stores, FAO Schwarz flagship store and kkplus kidsland. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
Shanghai, China, October 18, 2022 – (SEAPRWire) – The EqualOcean Summit for Globalization 2022 (ESG2022) will be held in Shanghai on November 8 during the 5th China International Import Expo (CIIE) by the globalization think tank EqualOcean. The summit will focus on the third generation of global entrepreneurs and respond to China’s promotion of high-level opening up from the perspective of industry research. ESG2022 will be the first cross-boundary communication platform for entrepreneurs, investors, scholars, and diplomats. It is of special significance to hold high-level market-driven activities during the “CIIE”. Other highlights include: The “2022 China Brand Globalization Index Report” will be released and the list of “Global Brand 100” will be announced;The “Chinese Brand Globalization Resource Handbook 2022” will be released, and representative service providers in each field will be promoted;“50 Global Young Leaders in China’s globalization ” and “50 Global Leaders in China’s globalization ” will be released to express a new voice of the global generation;Senior diplomats and well-known scholars of international relations will attend and give macro guidance to global entrepreneurs;Representative enterprises from the industry chain will be present at the seminar, covering all ecosystems of globalization, and insightful communication and links will be made on-site. Some of the confirmed guests include: Lin Minwang, professor at the Institute of International Studies of Fudan University and expert on Indian issues; Li Wei, professor at Renmin University of China and expert of the United States issues; Xu Liping, researcher at the Chinese Academy of Social Sciences and expert of Southeast Asia issues; Sun Degang, professor from the Institute of International Studies of Fudan University, also an expert on Middle East issues; Wang Guanchun, founder of LAIYE Technology; Hao Yusheng, chief representative of NASDAQ China; Song Xiangqian, chairman of Harvest Capital; Li Feng, founding partner of FREES FUND Capital; Jiang Shun, partner of INCAPITAL; Shu Chang, vice-chairman of China Youth Entrepreneurs Association; Pei Yigen, vice-chairman of Shanghai Service Federation; Zhang Peng, executive chairman of Beijing Youth Entrepreneurs Association; and Wen Jing, assistant researcher of Strategy and Security Research Center Tsinghua University, etc. ESG2022’s strategic partner “Wu Jianmin Public Welfare Foundation” will coordinate several senior diplomats to attend the summit and hold a closed-door panel to give macro-level guidance to entrepreneurs who are going for globalization/going overseas. ESG2022 will invite representative platforms, consumer brands, and technology companies in globalization field, including Alibaba International, AliExpress, Amazon, TikTok, AliCloud, Meta, Anker Innovation, NIO, Geek+, NEIWAI, XAG Technology, Rokid, ninebot, moody, PatPat, Cyclone-robotics, dreame, Ecoflow, Westwell Technology, RENOGY, Roborock Technology, Insta360, CooHom, Jushuitan ERP, Muzen Radio, 42Verse, etc. In addition, the most representative venture capital firms and financial advisory firms in the globalization direction will be invited, including SEQUOIA Capital, Gaorong Capital, 5Y Capital, Blue Lake Capital, Yunqi Partners, Fosun RZ Capital, eWTP Arabia Capital, LightHouse Capital, Index Capital, Yiren Capital, Foresight Capital, Wavierider Capital, etc. ESG 2022 Agenda 9:15-9:30/ Government Official’s Address9:30-9:50/ Report release: The 2022 China Brand Globalization Index Report9:50-10:00/ Launch ceremony: Alliance for China’s Brands and Globalization & Brand Globalization Intellects10:00-10:45/ Roundtable: China’s Globalization Strategy Outlook10:45-11:30/ Roundtable: Crosstalk of a Global-born Generation11:30-12:15/ Roundtable: Opportunities for China’s Brands to Go Global – Observations from Diplomats12:15-12:20/ Award session 1: 50 Global Leaders in China’s globalization12:20-13:50/ Lunch Break14:30-14:20/ Keynote: Opportunities and Challenges for China in the Next 10 Years14:20-15:05/ Roundtable: How to Build a Global Brand15:05-15:25/ Keynote: Forging China’s Global Brands15:25-16:10/ Roundtable: Entrepreneurship Across Continents16:10-16:30/ Keynote: Infrastructure for Globalization16:30-17:15/ Roundtable: Service Providers on Building a Global Brand17:15-17:35/ Keynote: Investors’ View: Business and Investment Opportunities in the Tide of Globalization17:35-17:40/ Award session 2: TOP Investment Institutions/FA/Service Providers for China’s Globalization Our event will be held during the fifth China International Import Expo (CIIE), where national leaders, government officials, diplomats from various countries and management from famous enterprises from home and abroad will gather in Shanghai. ESG2022 will take advantage of the CIIE to raise the voice of the third generation of global entrepreneurs and respond to the national construction of high-level opening up from our perspectives. We cordially invite entrepreneurs, investors and representatives from all segments of the industry, who are interested in the direction of globalization/going abroad, to come to Shanghai on November 8 to participate and witness together. About ESG2022 and EqualOcean ESG2022, known as EqualOcean Summit For Globalization 2022, is positioned as the top industry conference that brings together the third generation of global entrepreneurs and global brands. ESG2022 will be held in Shanghai on November 8, 2022 during the fifth China International Import Expo (CIIE), and will include not only the most representative global entrepreneurs, brand leaders and investors, but also government representatives, academics, diplomats in China and representatives of international organizations. ESG2022 will release “2022 China Brand Globalization Index Report”, “2022 China Brand Globalization Resource Handbook 2022 Edition”, “2022 China 50 Young Leaders in Globalization”, “2022 China 50 Leaders in Globalization”, etc. Founded in November 2018, EqualOcean is a business information platform and think tank that focuses on Chinese brands going global and on helping overseas investors or organizations to grasp China’s development opportunities. For clients from China, EqualOcean provides macro political and economic analysis, overseas market and industry research, brand international makeup photos, overseas resource building, etc. EqualOcean has both Chinese and English websites, and is one of the very few organizations in China with the ability to write in-depth reports in English. EqualOcean’s global partners include Bloomberg Terminal, Refinitiv, SeekingAlpha, Nasdaq, ACN Newswire, SeaPRwire and other platforms. EqualOcean’s business analysts are frequently interviewed by Wall Street Journal, New York Times, Financial Times, SCMP and other well-known media outlets. ESG2022 is now in the process of registration. For more information please visit EqualOcean’s website. If you have any questions about ESG2022, please feel free to contact us at our Wechat official account or via LinkedIn(EqualOcean). Media contact Email address: lena@equalocean.com Official website: https://equalocean.com The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
HONG KONG, Oct 10, 2022 - (ACN Newswire via SEAPRWire.com) - "Take practical action in a down-to-earth manner and aim high to achieve growth" is the long-standing company philosophy of China Wantian Holdings Limited ("China Wantian Holdings", together with its subsidiaries, the "Group"; Stock Code: 1854.HK). As a green enterprise engaged mainly in environmental protection and technology, retail, catering and fresh food supply, China Wantian Holdings has actively supported China's Greater Bay Area (GBA) development plan and net-zero carbon emissions vision in recent years, while outlining its development path for the GBA and striving to become one of the region's leading green brands. At a prize-giving ceremony yesterday, Dr. HOOY Kok Wai, Founding President of Guangdong - Hong Kong - Macau Greater Bay Area Industry and Commerce Federation, Vice Chairman of Perfect (China) and Chairman of the Board of China Wantian Holdings, was honoured with the 17th World Outstanding Chinese Award. Mr. ZHONG Xueyong, Founding Chairman of Guangdong - Hong Kong - Macau Greater Bay Area Industry and Commerce Federation, Co-Chairman of Wangu Group and Chief Executive Officer and Executive Director of China Wantian Holdings, was presented with the 3rd World Outstanding Chinese Youth Entrepreneur Award. Dr. HOOY Kok Wai and Mr. ZHONG Xueyong received the awards in recognition of their outstanding performance and achievements in the industry, and their active participation in public welfare affairs over the years, contributing to the social economy and helping to improve people's lives.Dr. HOOY Kok Wai, Chairman of the Board of China Wantian Holdings, was presented with the 17th World Outstanding Chinese Award.Mr. ZHONG Xueyong, Chief Executive Officer and Executive Director of China Wantian Holdings, was presented with the 3rd World Outstanding Chinese Youth Entrepreneur Award.Dr. HOOY Kok Wai (left), Chairman of the Board of China Wantian Holdings, took photo after receiving Lincoln University's honorary doctorate degree. As a Chairman of the Board at China Wantian Holdings and Vice-chairman of Perfect (China) Co., Ltd., Dr. HOOY Kok Wai brings to bear more than 30 years' deep experience of management and business development. He is also a renowned Chinese entrepreneur who focuses on improving people's lives. Dr. HOOY Kok Wai started his business in 1980. He was invited by his close friend Mr. Koo Yuen Kim, a third-generation member of the Chinese-Malaysian community, to visit Zhongshan, in Guangdong Province, where they co-founded Perfect Commodity Co., Ltd. ("Perfect Co.") in 1993. Over the years, Perfect Co. has continued to grow and has become a modern enterprise engaging in scientific research, production, sales and services. Making cumulative tax contribution of around RMB38.8 billion, Perfect Co. has become the largest taxpayer in Zhongshan. Adhering to a lifelong philosophy of positivity, optimism and hard work, Dr. HOOY Kok Wai contemplated starting a second business, and joined forces with Mr. ZHONG Xueyong to lead China Wantian Holdings, developing it as an enterprise that safeguards people's food safety and promotes the urban economy to fulfil the promise of helping people live better lives. In recent years, China Wantian Holdings has actively responded to China's call to improve people's health, embracing green development and adopting a mission to enable thousands of families to eat well every day, and it has worked tirelessly to become a leading lifestyle service provider in China.Mr. ZHONG Xueyong, the Group's Chief Executive Officer, is a post-1980s generation young entrepreneur, community leader and philanthropist. Mustering a Hakka spirit of diligence, innovation and pragmatism, Mr. ZHONG Xueyong founded Wangu Group in 2012 and accumulated the means to contribute to society through developing his business. In 2015, Mr. ZHONG Xueyong established Wangu Shopping Basket Plaza, a landmark project with both exterior and inner functions, making a commitment to developing it as a five-star safe food market providing air and water purification and one of the Zhongshan government's major large-scale livelihood projects. In 2018, with Dr. HOOY Kok Wai, Mr. ZHONG Xueyong founded WG Sky Farm International Group, which develops the rooftops of schools, government offices, hospitals and factories to create distinctive sky farm and grow organic vegetables, advancing healthy lifestyles, environmental protection and afforestation. In addition to setting an example for a new generation of entrepreneurs, Mr. ZHONG Xueyong never forgets his origins and always remembers past kindnesses he has received. He endeavours ceaselessly to contribute to society, helping disadvantaged members of the community and actively participating in the promotion of public welfare. As of 2021, he had organized more than 100 public welfare activities and had donated tens of millions renminbi to the disadvantaged group, directly benefiting over 100,000 people.The honours of the World Outstanding Chinese Award and the World Outstanding Chinese Youth Entrepreneur Award recognise the business philosophies and social influence of Dr. HOOY Kok Wai and Mr. ZHONG Xueyong over the years, during which they have distinguished themselves through their kindness and by cultivating a strong sense of social responsibility among China Wantian Holdings' management. "For being well prepared and raring to go, god rewards those who work hard," is Dr. HOOY Kok Wai's motto. As management at the Group, Dr. HOOY Kok Wai believes that he must set a good example for his employees. He remains ever-mindful of his origins, he always returns expressions of kindness he has been shown, and he devotes himself tirelessly to helping others succeed. He also strives to achieve further breakthroughs and surpass himself in corporate development. Mr. ZHONG Xueyong says it is his aspiration to contribute to livelihoods nationwide through entrepreneurship. To make an even greater contribution to society, he aspires to supply the Chinese people with the highest-quality food ingredients by continuously upgrading and expanding China Wantian Holdings' business. Driven by its mission of enabling thousands of families to eat well every day, China Wantian Holdings is committed to becoming a leading lifestyle service provider in China. Leveraging its two leaders' solid experience of business operations and strong social networks in China, the Group will actively cooperate with the Chinese government in developing a philosophy of modern agriculture technology and green environmental protection by creating fertile land on unused rooftop spaces to increase the proportion of urban greenery. The Group will promote environmental education at enterprises and in schools in order to support the sustainable development of the GBA. In the future, leveraging the honours received by Dr. HOOY Kok Wai and Mr. ZHONG Xueyong, China Wantian Holdings will proactively establish a development path for the GBA in line with China's national development plan and net-zero carbon emissions target, with the aim of becoming a leading green enterprise brand in the region.The 3rd Guangdong-Hong Kong-Macao Greater Bay Area Outstanding Young Entrepreneur Award Ceremony, co-organized and sponsored by China Wantian Holdings, was held simultaneously in Hong Kong, Macau and Shenzhen on 21 September 2022. One-hundred-and-two winners were selected from fields including semiconductors, autonomous driving, healthcare, home economics and the Internet of Things, based on their contributions and outstanding achievements in the GBA. The event was designated by the Government of the Hong Kong Special Administrative Region as one of the activities to celebrate the 25th anniversary of the city's returning to Chinese sovereignty. Mr. John Lee, Hong Kong Special Administrative Region's Chief Executive, attended and delivered a speech at the ceremony. At the event, Mr. ZHONG Xueyong was invited to shake hands and have his photograph taken with Mr. Lee.The award aims to identify the highest-potential and most representative young entrepreneurs in the GBA and recognise their outstanding contributions to promoting the integrated development of the region. It is hoped that more young talents will be encouraged by the two China Wantian Holdings entrepreneurs' success at the awards and seize opportunities to engage with the development of the GBA. China Wantian Holdings is actively engaged in the development of the GBA, and is committed to becoming a leading green brand in the region to contribute more to its economy and exquisite lifestyle in the society. The Group's management also hopes that young talents will pursue the opportunities the GBA offers and help the region to excel in harmony with the philosophy of the Guangdong-Hong Kong-Macao Greater Bay Area Outstanding Young Entrepreneur Award Ceremony.About China Wantian Holdings LimitedChina Wantian Holdings (1854.HK) is an investment holding company. The Group is principally engaged in sourcing, processing and supplying food ingredients, with a focus on the provision of vegetables and fruit to food service operators in Hong Kong. It supplies in excess of 1,300 food ingredients to more than 480 customers. In May 2022, China Wantian Holdings established its Greater Bay Area headquarters in Shenzhen, marking its official debut in the Greater Bay Area market. The Group will focus on developing three main businesses in this market, including fresh food supply, retail and catering, as well as environmental protection and technology and actively establish a leading green brand in the Greater Bay Area to provide customers with fresh, healthy and safe food.For more details, please visit: chinawantian.etnet.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
SHANGHAI, CHINA, Oct 10, 2022 - (亚太商讯 via SEAPRWire.com) - 华领医药（「公司」，香港联交所股份代号：2552.HK）今天宣布，公司研发的全球首创（first-in-class）新药葡萄糖激酶激活剂（GKA）华堂宁(R)（多格列艾汀片，dorzagliatin，HMS5552）已于10月8日获得中国国家药品监督管理局（NMPA）的上市批准。华堂宁(R)获批两个适应症，即单独用药治疗未经药物治疗的2型糖尿病患者，或者在单独使用二甲双胍血糖控制不佳时，与二甲双胍联合使用，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于中度至终末期肾功能损伤的2型糖尿病患者的口服降糖药物。同时，临床试验表明，华堂宁(R)联合恩格列净（SGLT-2抑制剂）和西格列汀（DPP-4抑制剂）用药的效果优于单独用药，有望更好地改善2型糖尿病患者的血糖控制和胰岛功能。华堂宁(R)是全球范围内首个获批上市的葡萄糖激酶激活剂药物，是过去十年来糖尿病领域首个全新机制的原创新药，也是首次在中国推出的2型糖尿病全球首创新药。这一里程碑代表着中国生物医药产业运用先进的创新科学理念实现中国患者临床需求的重要进展。华堂宁(R)是华领医药运用「中西合璧，联合创新，共享共赢」的运营模式研发出的首个全球首创新药，标志着中华引领医药创新步入新的历史阶段。华堂宁(R)是华领医药坚持「患者为先、创新为本、良药为民」的宗旨，针对中国糖尿病患者疾病特征，自主研发的全球首创新药。华堂宁®的研发项目自启动以来，其进展就获得了新药研发行业和国家药品审评审批部门的高度关注与重视，连续入选国家科技部「十二五」和「十三五」重大新药创制专项。华堂宁(R)具有新概念、新机制、新结构、新技术和新疗效等「五新」特征，从临床前实验，到Ⅰ期、Ⅱ期、Ⅲ期临床试验，其进程均由中国研发团队和中国临床研究者主导设计完成，不仅实现了从创新概念转化为创新产品的重大研发突破，也为中国开发全球首创新药探索出了一条自主研发的可行路径。华堂宁(R)的成功获批也意味着，国内外多家药企历经20余年的开发历程后，终于迎来全球首款获批的GKA类药物，实现零的突破。获批上市后，华领医药将与领军企业拜耳共同推动华堂宁®在中国的商业化推广，以造福糖尿病患者及其家庭。在全球范围内，糖尿病发病率持续增长。国际糖尿病联盟（IDF）最新数据显示， 2021年全球成年糖尿病患者人数达到5.37亿，相比2019年增加7400万，增幅16%。2021年，糖尿病及其并发症造成的全球卫生支出约为9660亿美元。我国的糖尿病防控形势也不容乐观，2021年糖尿病患者人数已经达到1.4亿，其中约7283万名患者尚未被确诊治疗，比例高达51.7%。与此同时，糖尿病患者血糖大幅度波动又导致了心脑血管疾病、肾病、眼病、糖尿病足等一系列糖尿病并发症的发生，极大地影响了糖尿病患者的生存需求和生活质量，给患者及其家庭带来沉重的疾病负担。因此，改善2型糖尿病患者的血糖稳态，维持患者的高TIR （time in range，血糖在目标范围内时间）已经成为糖尿病治疗管理的重要目标。根据国务院办公厅印发的「十四五」国民健康规划通知，提高糖尿病等重大慢性病综合防治能力将继续作为国家重点关注的健康问题，预计「十四五」期间2型糖尿病患者基层规范管理服务率达到65%以上。华堂宁(R)的成功获批上市，顺应了中国医药产业发展和国民健康水平提高的国家战略。高速增长的糖尿病患者人数和巨大的糖尿病药物市场容量均表明，糖尿病领域存在尚未满足的医疗需求。根据「修复传感，重塑稳态，从源头上治疗糖尿病」的原创科学概念，华领医药直击2型糖尿病患者血糖传感器失灵的根本病因，成功开发出华堂宁(R)这款全球首创新药。临床研究表明，华堂宁(R)可以修复糖尿病患者受损的葡萄糖激酶传感器功能，改善患者的血糖自主调控能力，有望从源头上控制2型糖尿病的进展和并发症的发生。作为全新一类2型糖尿病治疗药物，华堂宁(R)的研发也获得了国际学术界的持续关注。 2018年，其II期临床研究结果发表在国际高级医学期刊《柳叶刀-糖尿病与内分泌》上，为该杂志首次发表来自中国的关于2型糖尿病原创新药的临床研究成果；今年5月，国际顶级医学期刊《自然-医学》同时发表其两篇III期研究结果的同行评议论文，分别详细展示和描述了单药（SEED研究）以及联合二甲双胍（DAWN研究）治疗2型糖尿病的临床研究结果，充分肯定了华堂宁(R)作为全新机制的糖尿病新药，具有显著的安全优势，具备改善2型糖尿病患者胰岛功能的机理特征，并指出华堂宁(R)在临床试验中显示出了在糖尿病肾病患者中的独特优势。 其它临床研究数据还表明，华堂宁(R)在与DPP-4抑制剂、SGLT-2抑制剂的联合用药在控制血糖方面显示出了明显增效作用,安全性良好，在不同控糖需求和不同疾病阶段的2型糖尿病患者中具有广泛的应用潜力，并且有望通过恢复胰岛素早相分泌和持久改善β细胞功能，成为实现糖尿病缓解的重要途径。未来，华领医药还将继续探索华堂宁(R)在2型糖尿病停药缓解，以及与现有9类糖尿病药品联合用药等方面的潜力，力争满足糖尿病预防、缓解和推迟并发症等重大社会需求，并将中国创新推向全球市场。拜耳集团处方药事业部全球执行副总裁兼中国区总裁、拜耳集团大中华区总裁周晓兰女士表示：「拜耳一直深耕糖尿病治疗领域，助力中国糖尿病防治事业的发展。华堂宁®将与拜唐苹(R) ——首个拥有糖耐量受损（IGT）适应症的口服降糖药，以及持续葡萄糖监测系统（CGMs）一起，建立起针对中国2型糖尿病患者的从预防到治疗的全病程管理，并通过实时血糖监测来实现『稳态降糖』的目标；同时拜耳还将积极探索数字化解决方案，来帮助中国数以亿计的患者早日实现远离糖尿病困扰的美好愿景。」华领医药创始人、首席执行官、首席科学官陈力博士表示：「华堂宁(R)的成功获批对华领医药来说是重大的里程碑事件，也标志着中国创新药产业进入了新的发展的新阶段。糖尿病慢病管理是关系国计民生的重大战略问题，华领医药坚持『中华引领医药创新』的初心，在剧烈的国际竞争中，苦干10年时间实现零的突破，与华领的研究者和合作者们共同开发出这款全球首创、中国首发的糖尿病新药。这是所有参与华堂宁(R)研发的中国科学家、临床医生和合作者们的共同成果，我们对于华堂宁(R)的获批上市感到非常骄傲，也非常感谢所有人对华堂宁(R)的获批上市做出的艰苦努力和全心奉献。同时，华领医药期待与拜耳深度融合、活力全开，全面加速华堂宁(R)的商业化进程，为中国上亿的糖尿病患者带来糖尿病预防、治疗和缓解的新希望，提升糖尿病防治标准，为实现健康中国2030的国家战略贡献力量。」关于华堂宁(R)华堂宁(R)（多格列艾汀片）是一款全球首创、全新机制、异位变构功能的葡萄糖激酶激活剂，用于单独用药，或者在单独使用盐酸二甲双胍血糖控制不佳时，与盐酸二甲双胍联合使用，配合饮食和运动改善成人2型糖尿病患者的血糖控制。华堂宁(R)有望通过修复胰腺-肠道-肝脏受损的葡萄糖激酶功能，实现一靶多点，协调控糖，可以血糖依赖性地调节控糖激素胰岛素、GLP-1和胰高糖素的分泌，改善糖尿病患者的胰岛素早相分泌和处置指数，对恢复血糖稳态、实现糖尿病的停药缓解的潜力。华堂宁®在单药治疗和与二甲双胍联合用药的两项III期注册临床研究中，在受试者中展示出了显著的降糖效果，能够有效降低餐后血糖，且低血糖风险低、安全耐受性好。华堂宁(R)具有良好药物剂量和血液暴露的线性关系，靶器官分布于胰腺、肠道、肝脏，肾脏排泄低，在终末期肾病（ESRD）患者和健康受试者的药代动力学特征相似，肾功能不全患者无需调整剂量。华堂宁(R)独特的作用机制、良好的药代动力学特征和良好的安全性、耐受性，使其成为全新一类糖尿病治疗药物。关于华领华领医药是一家创立于中国的创新药物研发公司，专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。其核心产品华堂宁(R)（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，在中国完成了播种研究(SEED)和黎明研究(DAWN)两项III期注册试验，并已正式获得中国国家药品监督管理局（NMPA）的新药上市批准。这款全球首创的葡萄糖激酶激活剂在临床研究中展示了糖尿病缓解的潜力，以帮助全球数亿糖尿病患者。关于拜耳拜耳作为一家跨国企业，在生命科学领域的健康与农业方面具有核心竞争力。公司致力于通过产品和服务，帮助人们克服全球人口不断增长和老龄化带来的重大挑战，造福人类和地球繁荣发展。拜耳致力于推动可持续发展并对业务产生积极影响。同时，集团还通过科技创新和业务增长来提升盈利能力并创造价值。在全球，拜耳品牌代表着可信、可靠及优质。在2020财年，拜耳的员工人数约为100,000名，销售额为414亿欧元。不计特殊项目的研究开发投入为49亿欧元。更多信息请见 www.bayer.com 。关于华领-拜耳双方合作2020年8月，跨国医药企业拜耳与中国创新药物研发公司华领医药宣布就全新首创糖尿病治疗药物多格列艾汀在中国建立战略合作。此项合作旨在充分发挥拜耳在中国糖尿病管理领域的深厚优势以及华领医药在糖尿病领域的研发专长，双方合力提供全新的治疗方案选择，造福中国亿万糖尿病患者。根据合作协议，华领医药作为药品上市许可持有人将负责临床研究，药品注册，药品供应及配送；拜耳作为推广服务提供方将负责该产品在中国的市场营销，推广以及医学教育活动。拜耳处方药中国合作创新中心促成了此次合作。作为全球医药领域的领导者，拜耳致力于携手外部合作伙伴，共同推动突破性创新，为患者健康带来积极转变，实现「合作创新，携手治愈」的目标。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
SHANGHAI, CHINA, Oct 10, 2022 - (亚太商讯 via SEAPRWire.com) - 华领医药（「公司」，香港联交所股份代号：2552.HK）今天宣布，公司研发的全球首创（first-in-class）新药葡萄糖激酶激活剂（GKA）华堂宁®（多格列艾汀片，dorzagliatin，HMS5552）已于10月8日获得中国国家药品监督管理局（NMPA）的上市批准。华堂宁®获批两个适应症，即单独用药治疗未经药物治疗的2型糖尿病患者，或者在单独使用二甲双胍血糖控制不佳时，与二甲双胍联合使用，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于中度至终末期肾功能损伤的2型糖尿病患者的口服降糖药物。同时，临床试验表明，华堂宁®联合恩格列净（SGLT-2抑制剂）和西格列汀（DPP-4抑制剂）用药的效果优于单独用药，有望更好地改善2型糖尿病患者的血糖控制和胰岛功能。华堂宁®是全球范围内首个获批上市的葡萄糖激酶激活剂药物，是过去十年来糖尿病领域首个全新机制的原创新药，也是首次在中国推出的2型糖尿病全球首创新药。这一里程碑代表着中国生物医药产业运用先进的创新科学理念实现中国患者临床需求的重要进展。华堂宁®是华领医药运用「中西合璧，联合创新，共享共赢」的运营模式研发出的首个全球首创新药，标志着中华引领医药创新步入新的历史阶段。华堂宁®是华领医药坚持「患者为先、创新为本、良药为民」的宗旨，针对中国糖尿病患者疾病特征，自主研发的全球首创新药。华堂宁®的研发项目自启动以来，其进展就获得了新药研发行业和国家药品审评审批部门的高度关注与重视，连续入选国家科技部「十二五」和「十三五」重大新药创制专项。华堂宁®具有新概念、新机制、新结构、新技术和新疗效等「五新」特征，从临床前实验，到Ⅰ期、Ⅱ期、Ⅲ期临床试验，其进程均由中国研发团队和中国临床研究者主导设计完成，不仅实现了从创新概念转化为创新产品的重大研发突破，也为中国开发全球首创新药探索出了一条自主研发的可行路径。华堂宁®的成功获批也意味着，国内外多家药企历经20余年的开发历程后，终于迎来全球首款获批的GKA类药物，实现零的突破。获批上市后，华领医药将与领军企业拜耳共同推动华堂宁®在中国的商业化推广，以造福糖尿病患者及其家庭。在全球范围内，糖尿病发病率持续增长。国际糖尿病联盟（IDF）最新数据显示， 2021年全球成年糖尿病患者人数达到5.37亿，相比2019年增加7400万，增幅16%。2021年，糖尿病及其并发症造成的全球卫生支出约为9660亿美元。我国的糖尿病防控形势也不容乐观，2021年糖尿病患者人数已经达到1.4亿，其中约7283万名患者尚未被确诊治疗，比例高达51.7%。与此同时，糖尿病患者血糖大幅度波动又导致了心脑血管疾病、肾病、眼病、糖尿病足等一系列糖尿病并发症的发生，极大地影响了糖尿病患者的生存需求和生活质量，给患者及其家庭带来沉重的疾病负担。因此，改善2型糖尿病患者的血糖稳态，维持患者的高TIR （time in range，血糖在目标范围内时间）已经成为糖尿病治疗管理的重要目标。根据国务院办公厅印发的「十四五」国民健康规划通知，提高糖尿病等重大慢性病综合防治能力将继续作为国家重点关注的健康问题，预计「十四五」期间2型糖尿病患者基层规范管理服务率达到65%以上。华堂宁®的成功获批上市，顺应了中国医药产业发展和国民健康水平提高的国家战略。高速增长的糖尿病患者人数和巨大的糖尿病药物市场容量均表明，糖尿病领域存在尚未满足的医疗需求。根据「修复传感，重塑稳态，从源头上治疗糖尿病」的原创科学概念，华领医药直击2型糖尿病患者血糖传感器失灵的根本病因，成功开发出华堂宁®这款全球首创新药。临床研究表明，华堂宁®可以修复糖尿病患者受损的葡萄糖激酶传感器功能，改善患者的血糖自主调控能力，有望从源头上控制2型糖尿病的进展和并发症的发生。作为全新一类2型糖尿病治疗药物，华堂宁®的研发也获得了国际学术界的持续关注。 2018年，其II期临床研究结果发表在国际高级医学期刊《柳叶刀-糖尿病与内分泌》上，为该杂志首次发表来自中国的关于2型糖尿病原创新药的临床研究成果；今年5月，国际顶级医学期刊《自然-医学》同时发表其两篇III期研究结果的同行评议论文，分别详细展示和描述了单药（SEED研究）以及联合二甲双胍（DAWN研究）治疗2型糖尿病的临床研究结果，充分肯定了华堂宁®作为全新机制的糖尿病新药，具有显著的安全优势，具备改善2型糖尿病患者胰岛功能的机理特征，并指出华堂宁®在临床试验中显示出了在糖尿病肾病患者中的独特优势。 其它临床研究数据还表明，华堂宁®在与DPP-4抑制剂、SGLT-2抑制剂的联合用药在控制血糖方面显示出了明显增效作用,安全性良好，在不同控糖需求和不同疾病阶段的2型糖尿病患者中具有广泛的应用潜力，并且有望通过恢复胰岛素早相分泌和持久改善β细胞功能，成为实现糖尿病缓解的重要途径。未来，华领医药还将继续探索华堂宁®在2型糖尿病停药缓解，以及与现有9类糖尿病药品联合用药等方面的潜力，力争满足糖尿病预防、缓解和推迟并发症等重大社会需求，并将中国创新推向全球市场。拜耳集团处方药事业部全球执行副总裁兼中国区总裁、拜耳集团大中华区总裁周晓兰女士表示：「拜耳一直深耕糖尿病治疗领域，助力中国糖尿病防治事业的发展。华堂宁®将与拜唐苹® ——首个拥有糖耐量受损（IGT）适应症的口服降糖药，以及持续葡萄糖监测系统（CGMs）一起，建立起针对中国2型糖尿病患者的从预防到治疗的全病程管理，并通过实时血糖监测来实现『稳态降糖』的目标；同时拜耳还将积极探索数字化解决方案，来帮助中国数以亿计的患者早日实现远离糖尿病困扰的美好愿景。」华领医药创始人、首席执行官、首席科学官陈力博士表示：「华堂宁®的成功获批对华领医药来说是重大的里程碑事件，也标志着中国创新药产业进入了新的发展的新阶段。糖尿病慢病管理是关系国计民生的重大战略问题，华领医药坚持『中华引领医药创新』的初心，在剧烈的国际竞争中，苦干10年时间实现零的突破，与华领的研究者和合作者们共同开发出这款全球首创、中国首发的糖尿病新药。这是所有参与华堂宁®研发的中国科学家、临床医生和合作者们的共同成果，我们对于华堂宁®的获批上市感到非常骄傲，也非常感谢所有人对华堂宁®的获批上市做出的艰苦努力和全心奉献。同时，华领医药期待与拜耳深度融合、活力全开，全面加速华堂宁®的商业化进程，为中国上亿的糖尿病患者带来糖尿病预防、治疗和缓解的新希望，提升糖尿病防治标准，为实现健康中国2030的国家战略贡献力量。」关于华堂宁®华堂宁®（多格列艾汀片）是一款全球首创、全新机制、异位变构功能的葡萄糖激酶激活剂，用于单独用药，或者在单独使用盐酸二甲双胍血糖控制不佳时，与盐酸二甲双胍联合使用，配合饮食和运动改善成人2型糖尿病患者的血糖控制。华堂宁®有望通过修复胰腺-肠道-肝脏受损的葡萄糖激酶功能，实现一靶多点，协调控糖，可以血糖依赖性地调节控糖激素胰岛素、GLP-1和胰高糖素的分泌，改善糖尿病患者的胰岛素早相分泌和处置指数，对恢复血糖稳态、实现糖尿病的停药缓解的潜力。华堂宁®在单药治疗和与二甲双胍联合用药的两项III期注册临床研究中，在受试者中展示出了显著的降糖效果，能够有效降低餐后血糖，且低血糖风险低、安全耐受性好。华堂宁®具有良好药物剂量和血液暴露的线性关系，靶器官分布于胰腺、肠道、肝脏，肾脏排泄低，在终末期肾病（ESRD）患者和健康受试者的药代动力学特征相似，肾功能不全患者无需调整剂量。华堂宁®独特的作用机制、良好的药代动力学特征和良好的安全性、耐受性，使其成为全新一类糖尿病治疗药物。关于华领华领医药是一家创立于中国的创新药物研发公司，专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。其核心产品华堂宁®（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，在中国完成了播种研究(SEED)和黎明研究(DAWN)两项III期注册试验，并已正式获得中国国家药品监督管理局（NMPA）的新药上市批准。这款全球首创的葡萄糖激酶激活剂在临床研究中展示了糖尿病缓解的潜力，以帮助全球数亿糖尿病患者。关于拜耳拜耳作为一家跨国企业，在生命科学领域的健康与农业方面具有核心竞争力。公司致力于通过产品和服务，帮助人们克服全球人口不断增长和老龄化带来的重大挑战，造福人类和地球繁荣发展。拜耳致力于推动可持续发展并对业务产生积极影响。同时，集团还通过科技创新和业务增长来提升盈利能力并创造价值。在全球，拜耳品牌代表着可信、可靠及优质。在2020财年，拜耳的员工人数约为100,000名，销售额为414亿欧元。不计特殊项目的研究开发投入为49亿欧元。更多信息请见 www.bayer.com 。关于华领-拜耳双方合作2020年8月，跨国医药企业拜耳与中国创新药物研发公司华领医药宣布就全新首创糖尿病治疗药物多格列艾汀在中国建立战略合作。此项合作旨在充分发挥拜耳在中国糖尿病管理领域的深厚优势以及华领医药在糖尿病领域的研发专长，双方合力提供全新的治疗方案选择，造福中国亿万糖尿病患者。根据合作协议，华领医药作为药品上市许可持有人将负责临床研究，药品注册，药品供应及配送；拜耳作为推广服务提供方将负责该产品在中国的市场营销，推广以及医学教育活动。拜耳处方药中国合作创新中心促成了此次合作。作为全球医药领域的领导者，拜耳致力于携手外部合作伙伴，共同推动突破性创新，为患者健康带来积极转变，实现「合作创新，携手治愈」的目标。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
HONG KONG, Sep 25, 2022 - (ACN Newswire via SEAPRWire.com) - GalaxySpace, a Chinese commercial aerospace company, recently completed its latest financing round with a post-investment valuation of approximately RMB11 billion. As an existing shareholder, Legend Capital continued to support the company by following up on this financing round.Legend Capital first invested in GalaxySpace in 2018 and continued to follow up on the company's subsequent financing rounds in 2019, 2020 and 2022, increasing its investment layout of cutting-edge technology and supporting the development of GalaxySpace.Founded in 2018, GalaxySpace is the first unicorn enterprise in the field of commercial aerospace and satellite internet in China. Xu Ming, founder, chairman and CEO of GalaxySpace, said: "This round of financing will be mainly used for the R&D of satellite Internet-related technologies and the development of commercial applications. GalaxySpace will accelerate the R&D of core technologies such as stackable flat panel satellites, flexible multi-beam phased array technology, flexible solar wings, digital processing payloads, etc., and also the construction of mass-producing low-cost satellites. Step by step, we will move forward to the 6G era of the Internet of Everything."Nowadays, global space infrastructure construction has been developing rapidly, and commercial aerospace is becoming one of the new driving forces of the world's economic development. According to a Morgan Stanley report, the global space economy is expected to be worth $1 trillion by 2040, and the satellite Internet is expected to account for 50% or even 70% of the market growth.At present, GalaxySpace's new-generation stackable flat-panel satellite has entered the prototype development stage, which is also the first flat-panel satellite in China and will be launched early next year. It is believed that the development of stackable flat-panel satellites will promote the mass production of satellites and the rapid deployment of large-scale constellations. In the future, GalaxySpace will seize the development opportunities and fully utilize the advantages of small wins and rapid iteration of commercial aerospace to make a continuous innovative contribution to China's satellite Internet construction.About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
HONG KONG, Aug 30, 2022 - (ACN Newswire via SEAPRWire.com) - Nissin Foods Company Limited ("Nissin Foods" or the "Company", together with its subsidiaries, the "Group"; Stock code: 1475) has today announced its interim results for the six months ended 30 June 2022 ("the reporting period"). Highlights-- Revenue from the Hong Kong operations increased solidly by 11.4% year-on-year to HK$759.9 million, mainly attributable to the strong demand for instant noodles and frozen food products driven by the hoarding behaviour of consumers. Revenue from Mainland China operations increased by 8.7% to HK$1,273.2 million, thanks to the growth in sales volume of cup-type instant noodles. -- In the face of rising production costs and raw material prices, Nissin Foods will implement the second phase of its price adjustment strategy in Hong Kong, for the products that were not included in the first phase implemented in April 2022. Their ex-factory price will be adjusted upward by a high single-digit percentage on average, starting from September 2022. -- "Nissin Foodium", Nissin's inaugural membership programme for Hong Kong and Mainland China has been launched respectively in July and August 2022. The "Nissin Foodium" in the WeChat Mini Program offers the members a series of exclusive benefits, exciting rewards and interactive games. The Group's revenue increased by 9.7% year-on-year ("YoY") to HK2,033.1 million (2021: HK$1,853.8 million). The Group's EBITDA grew by 8.4% YoY to HK$305.1 million (2021: HK$281.3 million), representing an EBITDA margin of 15.0% (2021: 15.2%). Profit attributable to owners of the Company amounted to HK$164.9 million (2021: HK$170.9 million). The Group's basic earnings per share was 15.80 HK cents (2021: 15.94 HK cents). Hong Kong OperationsRevenue from the Hong Kong operations increased solidly by 11.4% YoY to HK$759.9 million (2021: HK$682.2 million), mainly attributable to the strong demand for instant noodles and frozen food products driven by the hoarding behaviour of consumers. Segment results amounted to HK$50.0 million (2021:HK$52.6 million), owing to the higher-than-usual production and logistics costs that occurred during the fifth wave of the pandemic. Revenue from the Hong Kong operations accounted for 37.4% (2021: 36.8%) of the Group's revenue. The improvement in the performance of both cup-type and bag-type instant noodles was obvious, as consumers were more inclined to stay at home. To further complement its instant noodles portfolio, the Group launched various new flavours under the "Roah", Nissin "U.F.O." and "Fuku" brands. Frozen food products also demonstrated a strong demand due to the resurgence of the pandemic in Hong Kong. For the "KAGOME" business, plant-based soy and oat milks were launched to promote nutritious and healthy choices to health-conscious consumers. The Group replicated the success of granola in Greater China in new markets in Southeast Asia. The sales volume grew considerably in Singapore and Thailand during the first half of the year. The fresh-cut vegetable business has seen growing demand, and the distribution channels have further expanded from supermarkets to restaurants. Mainland China OperationsRevenue from the Mainland China operations increased by 8.7% (in local currency: 8.4%) to HK$1,273.2 million (2021: HK$1,171.6 million) thanks to the growth in sales volume of cup-type instant noodles as consumers continued to favour higher-quality products, offset by a drop in the distribution business. Segment results increased favourably by 14.1% to HK$165.9 million (2021: HK$145.4 million), mainly attributable to the sound performance of organic revenue growth, coupled with the price adjustment implemented during the period. Revenue from the Mainland China operations accounted for 62.6% (2021: 63.2%) of the Group's revenue. As with "Cup Noodles" in Hong Kong, the Company has been upgrading the product in Mainland China to feature smoother noodle texture and a thicker soup base since May 2021. A positive response was received from customers, with the sales volume continuously expanding during the period under review. Also, the Company continued its geographical business expansion strategy in Mainland China and explored certain new markets in the Western and Northern regions of China. Leveraging its diversified product portfolio, it seized the opportunity to promote other product categories such as frozen pasta and ramen during the lockdown in Shanghai due to resurgence of COVID-19, and the sales volume of these products was considerably broadened as a result. ProspectsThe Group is cautiously optimistic about the long-term business development in the regions in which it operates and will continue to explore ways to better alleviate the cost pressure amid this competitive landscape. While the high prices of key raw materials such as wheat flour and palm oil are starting to decline, there remains a veil of uncertainty over the future outlook of the business environment considering the rising risk of worldwide stagflation. In Hong Kong, the cost pressure has not yet been fully released. In the face of rising production costs and raw material prices, the Group will implement the second phase of its price adjustment strategy for the products that were not included in the first phase implemented in April 2022, with an average increase of a high single-digit percentage to the ex-factory price, starting from September 2022.Furthermore, a new membership programme designed to strengthen the connection with consumers and bring them enjoyment has been launched in both Hong Kong and Mainland China in July and August 2022, respectively. The "Nissin Foodium" in the WeChat Mini Program offers members a series of exclusive benefits, exciting rewards and interactive games. To enjoy additional benefits and surprises, consumers are encouraged to scan the unique QR code on the products by using the mini program and complete various tasks to earn points. It aims to enhance the Group's customer retention rate, boost product sales and better understand consumer preferences. Building on a solid foundation, well-diversified product portfolio and the premiumisation strategy pursued, the Company is well-positioned to deliver continuous revenue and earnings growth, as well as expand business territories with increasing brand recognition in Hong Kong and Mainland China for the years ahead. Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, "Despite the challenging conditions arising from increasing raw material prices, the Group has achieved solid revenue growth in both Hong Kong and Mainland China for the first half of this year. Thanks to the continuous support from customers in both Hong Kong and Mainland China, our products are able to sustain the growth momentum. We are dedicated to pursuing a premiumisation strategy and providing good quality food to bring contentment and an enjoyable experience to our valuable consumers. 'Nissin Foodium' is our first membership programme and part of our efforts to enhance consumer experience and strengthen our connection with them. Leveraging our research and production capabilities, as well as our management and marketing expertise, we will continue to invest in our products, people and production, so as to strengthen our overall competitiveness and ensure sustainable growth." About Nissin Foods Company LimitedNissin Foods Company Limited (The "Group"; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China with a diversified portfolio of well-known and highly popular brands and the largest instant noodle company in Hong Kong. The Group officially established its presence in Hong Kong in 1984. The Group primarily manufactures and sells instant noodles, frozen foods and other food products under its two core corporate brands, namely "NISSIN" and "DOLL" together with a diversified portfolio of iconic household premium food brands. The Group's five flagship product brands, namely "Cup Noodles", "Demae Iccho", "Doll Instant Noodle", "Doll Dim Sum" and "Fuku" are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the "ECO Cup" concept and primarily focuses its sales efforts in first-and second-tier cities. Nissin Foods is a constituent of eight Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Consumer Goods & Services Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng SCHK ex-AH Companies Index, and Hang Seng Small Cap (Investable) Index. For more information, please visit www.nissingroup.com.hk. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)